Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study

Cardiovascular risks associated with adjuvant endocrine therapy in women with breast cancer: a population-based cohort study

Abstract Background Endocrine therapies, including tamoxifen (TMX) and aromatase inhibitors (AIs), are widely used in breast cancer treatment. This study aims to evaluate the cardiovascular risks associated with these therapies in different age groups of non-metastatic breast cancer patients. Method...

Full description

Saved in:
Bibliographic Details
Main Authors: Iokfai Cheang, Ying Gue, Mei-Zhen Wu, Jia-Yi Huang, Qing-Wen Ren, Ziqi Chen, Yi-Kei Tse, Hang-Long Li, Yap-Hang Chan, Hung-Fat Tse, Xinli Li, Gregory Y. H. Lip, Kai-Hang Yiu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Breast Cancer
Estrogen receptor
Tamoxifen
Aromatase inhibitors
Cardiovascular risk
Cardio-oncology
Online Access:https://doi.org/10.1186/s12885-025-14280-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14280-z

Similar Items